Summary Using a recently developed model for studying the biology of locally recurrent (LR) mammary tumours in the 13762NF rat mammary adenocarcinoma system, we examined the sensitivity to polymorphonuclear cell, macrophage and natural killer cell cytolysis. The parental MTF7(T20) cell line; the 'primary' tumours which arose following subcutaneous inoculation into the mammary fat pad, scl and sc3; and the local recurrences (following surgical excision) LRI and LRla from scl, and LR3 from sc3 were all cells generally resistant to specific PMN cytolysis. LPS-activated macrophages caused 25.1%, 38.7% and 58.8% specific cytolysis in MTF7, scl and LRI cells, respectively at E:T of 20:1 and 72h co-incubation. LRla, sc3 and LR3 lysis ranged from 0-4.4% under the same conditions. Non-activated macrophages did not lyse any of the cell lines. Locally recurrent and 'primary' tumour cell lines were also not lysed by naive NK cells (range 0.5-4.0% cytolysis). NK cells activated with bropirimine, a potent immunomodulator currently being studied in clinical trials, and/or interleukin-2 were mildly more effective at killing LR cells. Our results show that locally recurrent tumours exhibit heterogeneous sensitivities and are different from 'primary' tumour cells in sensitivities to immune cell killing, but they are not necessarily more or less sensitive. Results with bropirimine-activated or IL-2-activated NK cells emphasize that nonspecific activation is insufficient to eliminate all tumour subpopulations.
Local recurrence of breast carcinoma occurs in approximately 10-40% of patients initially treated with modified or radical mastectomies, depending upon a number of parameters including: nodal involvement at the time of surgery, primary tumour size and location, histologic type, whether primary and/or adjuvant therapy was administered and level of differentiation (Donnegan et al., 1966; Fisher et al., 1977; Toonkel et al., 1983) . Often regional relapse indicates a poor 5-or 10-year prognosis because systemic disease occurs shortly after diagnosis (Recht et al., 1985; KarabaliDalamaga et al., 1978; Patanaphan et al., 1984; Pearlman & Jochimsen, 1979) . Also sensitivity to treatment regimens are frequently different in recurrent tumours compared to the original primary tumour.
We have recently developed a model for examining factors important in the biology of mammary tumours which recurred following surgical excision of the primary 13762NF mammary adenocarcinoma tumour MTF7 . We have shown that cell lines derived from local recurrences exhibit heterogeneity in metastatic potentials , sensitivities to the commonly used chemotherapeutic agents Adriamycin and 5-fluoro-2'-deoxyuridine (FUdR) and ionizing radiation and cell surface and 2-dimensional gel protein patterns . Some of the populations were more malignant (i.e. metastatic) and some were less malignant than the primary tumour. Likewise, there was no trend towards increased resistance or sensitivity to a single therapeutic approach.
Significant differences in cell surface properties (Welch et al., 1988) of the locally recurrent tumours (both gains and losses) suggest that the antigenic profiles of locally recurrent tumour cells are different. Hence, one could suppose differences in cellular recognition by host defense mechanisms. Furthermore, a significant leukocyte infiltration into the primary (MTF7) tumour (Neri et al., 1982; Estrada et al., 1986) indicated that there was an immune response although ineffectual. Some of the inability of the immune system to cure is probably due to the overwhelming mass of the tumour (Hersh et al., 1980 ). Yet after removing a large portion (>>99%) of the tumour mass surgically, several rats still developed local recurrences which likewise exhibited marked immune cell infiltration. Therefore, we wanted to measure the sensitivity of the local recurrent tumour cell lines to polymorphonuclear cell (PMN), macrophage and natural killer cell (NK) cytolysis in order to determine whether locally recurring mammary tumours were more resistant to immune cell killing than the primary tumour. We also wanted to determine whether any changes in sensitivity to immune cell cytolysis correlated with changes in metastatic potential of the locally recurring tumours. Finally, we wanted to determine whether changes in immune cell sensitivity, if any, would be important determinants in designing immunotherapy protocols used to treat recurrent tumours.
Our results showed that recurrent tumours have often different sensitivities to immune cell cytolysis, but that there is no trend toward more or less sensitivity. The data also showed that nonspecific activation of natural killer cell populations may not be effective against all tumour subpopulations. (Neri et al., 1982) as previously described and depicted in Figure 1 . Briefly, MTF7(T20) was injected into the left inguinal mammary fat pad of agematched syngeneic female F344/NHsd rats and allowed to grow for 23 days. Resulting tumours were removed from individual rats under metofane (methoxyflurane, Pitman Moore, Washington Crossing, NJ) anaesthesia and established in tissue culture (scl and sc3). Some of the rats developed recurrent tumours at the site of surgical excision within 14 days. These were established in tissue culture (LR1 from the animal bearing scl and LR3 from the animal bearing sc3). Also, LRIa was established in tissue culture from a local recurrence of LR1.
Cells were grown in alpha-modified minimum essential medium (AMEM; Irvine Scientific, Irvine, CA) supplemented with 5% foetal bovine serum (Biocell, Carson, CA) and no antibiotics (cAMEM) in a 37°C humidified atmosphere containing 5% CO2. Cells were routinely grown in 100mm dishes (Corning Glass Works, Oneonta, NY) and passaged using 0.25% trypsin (GIBCO, Grand Island, NY) at a split ratio of 1:50 when the cultures became 80% confluent. All cell lines were routinely screened and found to be free of Mycoplasma contamination (Chen, 1977 (Wierenga et al., 1980) in 0.5ml sterile vehicle 100 (the Upjohn Company) 3 days prior to NK isolation (Lotzova et al., 1983) . For some experiments, peritoneal exudate cells were 'activated' in vitro with varying concentrations of rat IL-2 (Sigma, St. Louis, MO) which is one of the most potent NK cell activators known (Chun et al., 1985) .
PMN and macrophage cytolysis assays PMN were prepared and added to quadruplicate wells in Corning 24-well tissue culture plates which had been seeded 2-4h previously with 10,000 radiolabeled tumour cells. After adding PMN cells at the appropriate effector:target (E:T) ratios (total volume of 1 ml/well) the plates were covered and incubated at 37°C for 24h for PMN, and for 24, 48 or 72h for macrophage cytolysis. Macrophage cytolysis assays were performed according to previously published methods (North & Nicolson, 1985) with slight modifications. Briefly, macrophages were activated with 50 ng ml -I lipopolysaccharide (LPS; Sigma) added to each well. After incubation 900 jul aliquots of supernatant were gamma counted for experimental cpm released.
Specific cytolysis was calculated according to the following equation:
%c ytotoicity =Test cpm -spontaneous release cpm 100
Total cpm -spontaneous release cpm where test cpm, spontaneous release cpm, and total cpm represent the radioactivity in 900 p1 aliquots of the supernatant from the effector and target cell mixture, the supernatant of target cells alone, and lysed target cells alone.
NK cytolysis assay We measured susceptibility of locally recurrent 1 3762NF mammary adenocarcinoma cell sublines~o unstimulated and ABPP-stimulated NK cytolysis using the method of Li et al. (1987) 
Macrophage cytolysis
There was no appreciable cytolysis using unstimulated macrophages at any E:T or co-incubation time (data not shown) which also confirms previously reported observations (North & Nicolson, 1985) . Using LPS-activated macrophages, there was generally no macrophage mediated cytolysis of any cells at incubation times of 24 and 48 h (Table II) . At 72h, however, MTF7, scl, and LR1 were maximally lysed at 25.1%, 38.7% and 58.8% at E:T ratio of 20:1 (Table II) . MTF7 cytolysis sensitivity was similar to that previously described at 72h and at comparable E:T (North & Nicolson, 1985) . LR1 was lysed at a significantly (P<0.05) higher level than scl, and both were lysed at significantly higher levels than the 'parental' MTF7 line. Maximal lysis for LRIa, sc3 and LR3 ranged from 0 to 4.4%. Thus, there are locally recurrent lines that are more sensitive (scl and LR1) and more resistant (sc3, LR3 and LRla) than MTF7 to activated macrophage cytolysis. (Figure 2 ). Maximal cytolysis was 4% for LR3 and the range for all locally recurrent cell lines was 0.5-4.0%. If a nonspecific immunomodulator, bropirimine, is used to activate NK cells prior to isolation (Lotzova et al., 1983) , there is a slight increase in the ability of NK cells to cause 1 3762NF mammary adenocarcinoma cell killing, mostly at the highest E:T levels. ABPP-elicited NK cells caused up to 28% killing for sc3, but only at E:T of 100:1. Killing was well under 20% for all of the other LR sublines and parents at all of the E:T tested. In contrast, bropirimine-activated NK cells are able to kill 50% to almost 100% of YAC-IA cells at low (20:1) effector to target ratios (Figure 1 & Table III ). In separate experiments, E:T ratios up to 50:1 with the potent NK cell activator IL-2 alone or in combination with bropirimine resulted in a maximum tumour cell kill of 17% (Table III) . Use of NK cells activated with combinations of bropirimine and IL-2 were no more effective at killing 13762NF mammary adenocarcinoma cells or YAC-la cells than either drug alone for the most part (Table III) .
Discussion
It is now well accepted that most solid tumours are comprised of a heterogeneous mixture of cells which differ for multiple phenotypes (Heppner, 1984) . Likewise, it is becoming increasingly clear that tumour composition changes during the course of tumour growth and progression (Neri & Nicolson, 1981; and reviewed in Welch & Tomasovic, 1985; Nicolson, 1987) . The implications of dynamic heterogeneity have been discussed and widely studied; however, the mechanisms involved in controlling tumour diversification and tumour composition are still unknown. Likewise, the total impact of changing tumour composition is still being determined. It is already known that the generation and maintenance of heterogeneity are both tumour cell directed and tumour cell response to external environment (Welch, 1987, 1988; Welch & Tomasovic, 1985 (Fidler & Kripke, 1980) . Immune cells respond to subsets of tumour cells and eliminate immunogenic portions of the tumour mass. Besides host selective pressures, artificial selective pressures (i.e. therapy) can also reduce tumour mass. One could predict differences between tumours analyzed prior to and after therapy and that the latter would be more resistant to the same follow-up treatment (Goldie & Coldman, 1984) . Immune cells also are involved in changing properties of tumour cells by nontoxic mechanisms. For example, heterotypic embolus formation (Liotta et al., 1976 , Fidler et al., 1979 , use of enzymes secreted by immune cells Dabbous et al., 1986) and undetermined mechanisms are involved in changing metastatic potential (Fidler et al., 1979) . Therefore, these studies were designed to address the connection, if any, between immune cell responsiveness before and after surgery (well after effects of drugs, anaesthetic etc. were past). Since locally recurrent tumours often differ in malignant potentials and sensitivities to follow-up therapy, we hypothesized that some of the changes may be related, in part, to changes in sensitivity to immune cell killing.
Cancer therapy currently involves debulking (often with surgery, but also with radiation, chemotherapy and/or immunotherapy) and 'mopping up' with radiation therapy, chemotherapy or immunotherapy. Drift of tumour populations indicates that follow-up therapy may need to account for shifting populations or different proportions of subpopulations than were present in the primary tumour, therefore changes in sensitivities to individual treatment arms would be observed. Our previous results confirmed this hypothesis since locally recurrent tumour-derived sublines were apparently randomly assorted from the primary tumour for metastatic potentials and commonly used chemotherapy and radiation therapy approaches 1988) . There was some predictability in the phenotypic drift since many recurrences were indeed more resistant to 5-fluoro-2'-deoxyuridine (at the LD90 dose) compared to the primary tumours . Also, there were some common shifts in 2-dimensional and cell surface protein patterns for all of the recurrences compared to the primary (MTF7) cell line, in particular was the progressive loss of a Mr`%93,000 kDa sialoglycoprotein in all of the recurrences . Leukocyte infiltration generally appeared to increase in recurrences compared to the primary tumour in most cases; however, some tumour lines elicited less infiltration. And there was also evidence of zonal heterogeneity in host response which was apparent in different histologic sections.
Several immune cells have been shown to play a role in the metastatic properties of tumour cells (Fidler et al., 1979; Hanna, 1982 Hanna, , 1985 Gorelik et al., 1982; Glaves, 1983 ; (Fidler et al., 1979 ). Hanna and colleagues have shown that NK cells are highly efficient at clearing tumour cells from the circulation and susceptibility of tumour cells to NK-mediated killing is often, but not always, inversely correlated with metastatic potential (Hanna, 1982; (Fidler et al., 1985; Poste, 1984) . They have found that liposome-activated macrophages (muramyl dipeptide-containing liposomes) are capable of preventing and eradicating established micrometastases. North & Nicolson (1985) found that there was no correlation between metastatic potential of 13762NF mammary adenocarcinoma cell clones and sensitivity to LPS-activated-macrophagemediated cell lysis, intratumoural macrophages or thioglycolate-elicited macrophages. Our conclusions are similar with the recently derived locally recurrent tumour model. MTF7 and LR3 form approximately the same number lung colonies (>200 metastases per rat (Estrada et al., 1986) yet 20-25% of MTF7 versus 0-4% of LR3 cells are killed in a macrophage cytolysis assay. scl and sc3 form approximately onehalf as many lung colonies as MTF7 but macrophage killing occurs for 22-38% and 0-3% of the cells, respectively. Likewise, there is no pattern towards increased or decreased sensitivity to macrophage killing in the local recurrence lineages.
Polymorphonuclear cells make up a large percentage of the circulating leukocytes in human blood; however, PMN account for only 10-20% of circulating white blood cells in F344/NHsd rats. We have shown that PMN levels in the blood rise sharply in 13762NF mammary adenocarcinoma tumour-bearing rats and the increase is proportional to the metastatic potential of the tumour. The circulating neutrophils secrete high levels of collagenase IV and a heparan sulphate endoglycosidase suggesting that they may be assisting tumour cell extravasation . Glaves (1983) found that activation of PMN in the vasculature with trypan dye injection resulted in increased oxygen radical production and increased radiolabeled tumour cell clearance following intravenous inoculation. She proposed that PMN may be important in limiting metastatic potential by eliminating circulating B16 melanoma cells. While PMN in our experiments are completely active in that they respond to PMA and FMLP to degranulate or produce oxygen metabolites, they are essentially unable to kill 13762NF mammary adenocarcinoma locally recurrent tumour cells in the presence or absence of these agents. Others have shown that PMN are capable of killing tumour cells (Pickaver et al., 1972; Kondo et al., 1986; Lichenstein, 1987; Lichenstein & Kahle, 1985; Morikawa et al., 1985) . As with NK cells and macrophages, there was no trend towards increased resistance with the local recurrent lineages tested.
All of the results presented here are the result of interactions between a single immune cell type with tumour cells. Lack of cytotoxicity with NK or PMN may have limited meaning since there may be synergy in vivo. The results do, within these limits, allow direct comparison of sensitivities under the conditions described and the sensitivities are significantly different. Extrapolation to the complex situation in an immunocompetent host is difficult.
In summary, locally recurrent tumours differ significantly from the primary tumour for a variety of properties, including sensitivity to natural immune mechanisms. Some recurrences were significantly more sensitive to macrophage mediated cell killing while others were significantly more resistant. None of the 13762NF mammary adenocarcinoma sublines were sensitive to activated NK or PMN cell killing. And there was no apparent correlation in the sensitivity of a single cell line to one immune cell type to another immune cell type. These results imply that changes in cellular composition of locally recurrent tumours may overwhelm the body's ability to adapt to and to mount an effective immune response against all survivors. They do not imply that all of the recurrences are resistant to immune cell killing. Some, in fact, may be more sensitive. Our results do demonstrate that follow-up therapy for recurrent tumours, even treatment with nonspecific immunomodulators, must account for changes in tumour composition.
